Survival after brain or spinal cord neoplasms is poor and varies by diagnostic group, age, grade, treatment and pretreatment factors, and location and size of tumor. We carried out a study to investigate survival and factors affecting survival of all diagnostic types of second primary brain or spinal cord neoplasms.
INTRODUCTION
Five-year survival in the United Kingdom after childhood cancer is currently better than 75%, 1 and there is an increasing focus on late effects of treatment, including cardiac and pulmonary damage, infertility, and second primary neoplasms (SPNs). The most frequent types of brain or spinal cord tumors are gliomas and meningiomas. 5 Factors affecting survival of gliomas include age, sex, tumor grade, site and size of tumor, and treatment and pretreatment factors.
6-15 Current treatments are of limited value in improving survival.
The RARECARE study of rare cancers in Europe estimated 5-year relative survival to be 20% after all glial tumors of the CNS and pineal gland, and 15% after astrocytic tumors of the CNS. 18 Survival after diagnosis of the most malignant gliomas (glioblastomas) is often less than a year, 19 and although prognosis has improved with the use of combined chemotherapy and radiotherapy, this approach can achieve a median survival of only 14.6 months. 20 In contrast, most meningiomas are benign and prognosis is more favorable: 5-year survival of all grades combined is approximately 80%. [21] [22] [23] Malignant meningiomas have a poorer prognosis: RARECARE estimated relative survival to be 63% at 5 years for malignant and atypical meningiomas.
Published data on survival following second primary brain tumors among survivors of childhood cancer are limited. 24 To the best of our knowledge, this is the first study to investigate factors affecting survival after diagnosis of the entire spectrum of brain or spinal cord SPNs that develop after childhood cancer.
PATIENTS AND METHODS

British Childhood Cancer Survival Study
The British Childhood Cancer Survival Study (BCCSS) is a populationbased cohort study of late treatment toxicities in 17,980 individuals diagnosed in Britain with childhood cancer when they were younger than age 15 years, between 1940 and 1991 inclusive, and surviving 5 years or more after diagnosis. 25 All survivors at least age 16 years who are alive and contactable through their general practitioner were sent a questionnaire (n ϭ 13,211: www.bccss .bham.ac.uk). Ethical approval was obtained from the relevant multicenter research ethics committee and every local research ethics committee in Britain (a total of 212). At the time this article was written, 10,483 questionnaires were returned from 13,211 sent (79.4%).
Information from questionnaires on SPNs was complemented by flagging at the National Health Service Central Registers. Flagging is a means of informing the BCCSS when a survivor develops a subsequent primary neoplasm or dies. Flagging provides a systematic way of linking the entire population-based BCCSS cohort of 17,980 individuals with the national population-based cancer and death registration systems for the entire population of Britain. This linkage process is entirely population-based. The SPN diagnosis was confirmed from histopathology (or radiologic reports if there was no biopsy), often with an accompanying clinician's letter. All confirmed benign and malignant brain or spinal cord SPNs occurring after 5-year survival and before December 31, 2002 , that developed in any of the 17,980 5-year survivors were included in this study.
Any late recurrences or second primary gliomas that developed after primary childhood gliomas were reviewed in detail to confirm diagnosis through all diagnostic reports and to exclude recurrences, and they were checked by an international expert on pediatric neuropathology (D.W.E.).
Classification
SPNs were coded to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). 26 Cases were defined as BCCSS cohort members who developed a subsequent primary brain or spinal cord neoplasm of any histology or behavior (ICD-O fifth digit code 0 to 3) and were grouped into five categories according to the 2007 WHO classification 27 : (1) glioma and other neuroepithelial neoplasms (ICD codes 9380 to 9523, excluding codes 9470-9473); (2) meningioma (ICD codes 9530-9539); (3) primitive neuroectodermal tumor; ICD codes 9470-9473); (4) schwannoma (ICD codes 9560-9561); or (5) other/unclassified brain or spinal cord neoplasms. For this article, "glioma" refers to glioma and other neuroepithelial neoplasms (Appendix Table A1 , online only).
We classified grade of brain or spinal cord tumor using the WHO 2007 grading system 27 (I-IV for gliomas and I-III for meningiomas). For this analysis, we subdivided gliomas into grades "low" (I-II) and "high" (III-IV) and for meningiomas, grades "low" (I-II) and "high" (III). These groups also matched with the last digit of the ICD-O code (ie, 0-2 as "low" and 3 as "high"). For astrocytoma not otherwise specified (nonorgan specific) and glioma NOS, a low grade category was allocated, because it was considered likely that if these SPNs were high grade, the term glioblastoma would have been used. For ependymoma NOS and astroblastoma NOS, a high grade category was allocated (Appendix Table A1 ).
Statistical Methods
Analyses were run separately for meningiomas and gliomas because of their different anticipated survival prospects. Patients who died on the day the SPN was diagnosed contributed zero days to survival and were excluded from the statistical analysis (five meningiomas, one glioma: six patients contributed zero days to overall survival). The remaining 241 survivors were entered into relative survival and multivariate Cox regression analysis using Stata version 10.1 (StataCorp, College Station, TX). Statistical significance was taken at the 5% level (two-sided).
The following potentially explanatory factors with specified levels were considered: (1) sex: male or female; (2) age at first primary neoplasm (FPN We did not include "site of tumor" (Appendix Table A2 , online only) as a factor in the analysis because of the difficulty of allocating site into meaningful groups to include in statistical analysis.
Relative Survival
We calculated relative survival estimates with 95% CIs. Relative survival is the ratio of observed survival in a cohort of cancer patients to the expected survival in a comparable group of individuals from the general population. 28 Time of survival began with date of diagnosis of brain or spinal cord SPN. Exit was date of death, loss to follow-up, or December 31, 2006, if survivors were still alive, depending on which occurred first. P values for heterogeneity to test for significant differences in survival were calculated using generalized linear models with a Poisson error structure and special link function.
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Cox Regression
Tests for heterogeneity (H; from the likelihood ratio statistic) were used to investigate associations between each potential explanatory factor and rate of death after a brain or spinal cord SPN in a multivariable model that controlled for all factors identified a priori. Interval between FPN and SPN was not included in the multivariable model because of collinearity with age at SPN. Tests for linear trend (T) were undertaken for factors with better than categoric measurement properties by assigning increasing consecutive integer values to levels of the factor and a value of zero to the baseline level.
RESULTS
Characteristics and Description of Cohort
There were 247 brain or spinal cord SPNs: 73 gliomas (29.6%), 137 meningiomas (55.5%), 16 schwannomas (6.5%), and nine primitive neuroectodermal tumors (3.6%). The 12 "other" cases included three neoplasms of uncertain histopathology, one pituitary adenoma, one sarcoma, one malignant fibrous histiocytoma, two hemangiopericytomas, one hemangioglioblastoma, two malignant peripheral-nerve sheath tumors, and an Epstein-Barr virus-associated lymphoma. One hundred and nineteen of the 247 SPNs developed in males (48.2%) and 128 in females (51.8%). The most common FPNs were CNS neoplasms (117; 47.4%) and the second most common was acute lymphoblastic leukemia (69; 27.9%).
Mean interval to development of glioma from childhood cancer diagnosis was 17.4 years, 15.5 years for low-grade (n ϭ 31), 18.7 years for high-grade (grades 3-4; n ϭ 42), and 21.0 years for grade 4 (n ϭ 28). Mean interval to development of meningioma was 23.1 years, 23.5 years for low-grade (n ϭ 129) and 15.9 years for high-grade (n ϭ 8).
WHO Grade of Gliomas and Meningiomas
Of the gliomas with known grades, there were 28 grade 4, seven grade 3, three grade 2, and six grade 1 (Appendix Table A1 ). For astrocytoma NOS (n ϭ 15) and glioma NOS (n ϭ 7) with no allocated grade, a category of low grade was allocated. For astroblastoma (n ϭ 4) and ependymoma NOS (n ϭ 3) with no allocated grade, a high grade was allocated. For meningiomas with known grades, there were eight grade 3, seven grade 2, and 57 grade 1. For meningiomatosis NOS (n ϭ 7) and meningioma NOS (n ϭ 58) with no grade, these were assumed to be low grade.
Site of SPN
Seventy-three (29.6%) of the SPNs developed in frontal lobes, 27 (10.9%) in parietal lobes, 20 (8.1%) in temporal lobes, and 11 (4.5%) in occipital lobes (Appendix Table A2 ). Twenty-three SPNs (9.3%) developed in the cerebellum or cerebellar meninges, and 10 (4.0%) developed in the brainstem.
Underlying Cause of Death
There were 123 deaths, including 62 after gliomas (50.4%) and 42 after meningiomas (34.1%; Table 1 ). Most deaths were classified as death from SPN (90 of 123 or 73.2%). There were 14 deaths from FPN (11.4%) and 15 from treatment-related causes (12.2%). Treatmentrelated deaths included bronchopneumonia, other SPNs, heart disease, or other complications. The remaining four deaths (3.3%) were not treatment related (referred to as "Other").
Genetic Risk and Underlying Cause of Death
Twenty-six survivors had a known genetic syndrome with an increased risk of brain or spinal cord SPN ( Table 1) . Twelve of 73 patients (16.4%) with second primary gliomas (seven high-grade and five low-grade) had NF1. Five of 127 patients (3.9%) with second primary meningiomas (one high-grade with NF1, two low-grade with NF2, one low-grade with Gorlin's syndrome, one low-grade with tuberous sclerosis) had an associated genetic syndrome. Five lowgrade schwannomas in the cerebello-pontine angle were associated with NF2. Three other high-grade SPNs were associated with NF1 (a sarcoma, a malignant peripheral-nerve-sheath tumor, and a malignant neoplasm of uncertain diagnosis). One other low-grade SPN (hemangioblastoma) was associated with Von Hippel-Lindau syndrome. There were proportionately more deaths in the genetic risk category (18 of 26 or 69%) compared with those with no known associated genetic syndrome (105 of 221 or 47.5%). Three of 18 deaths (16.7%) in the genetic syndrome category were from other causes of death compared with one of 105 (1.0%) in those with no known associated genetic syndrome (Table 1) . Of the three other deaths in the genetic risk category, cause of death was from NF2 (two) and NF1 (one).
Survival and Factors Affecting Survival
There were 1,610.2 person-years of follow-up with a mean of 6.7 years per survivor after SPN diagnosis (Tables 2 and 3 
DISCUSSION
To the best of our knowledge, this is the first study to examine survival and factors affecting survival after the entire spectrum of SPNs of the brain or spinal cord develop subsequent to childhood cancer. Most SPNs developed as a result of treatment for the original childhood cancer. 3 This study included a large number of brain or spinal cord SPNs diagnosed after childhood cancer on the basis of data from a population-based cohort with links to nationwide population-based registries for cancer and death. Selection bias and loss to follow-up bias, both associated with hospital-based studies, are minimized.
Gliomas are the most common primary malignant brain tumor in the general population (approximately 80% of total). Glioblastoma is the most common subtype in adults (approximately 62% gliomas) and the most malignant. 30 In this study, there were 28 glioblastomas; however, 73% of the 73 gliomas were diagnosed in patients younger than age 30 years and would be expected to include more low-grade gliomas, which predominate in childhood and adolescence. Mean interval to development of glioma from childhood cancer diagnosis was 15.5 years for low-grade, 18.7 years for high-grade, and 21.0 years for WHO grade 4 gliomas. Many low-grade gliomas transform into malignant gliomas, and it may be possible to screen with a magnetic resonance imaging (MRI) scan to detect gliomas before malignant transformation. 31 ,32 Although we have not been able to determine whether malignant transformation from low-to highgrade gliomas occurred during this study, it is important to determine whether surveillance with MRI scans of this population could improve survival.
Five-year relative survival after second primary gliomas was 19.5% (95% CI, 8.6% to 33.7%) for males and females. Survival was poorer for high-grade (5-year relative survival, 4.9%; 95% CI, 0.8% to 14.6%) compared with low-grade gliomas (5-year relative survival, 38.9%; 95% CI, 22.1% to 55.4%; P Ͻ .001). This compares with 5-year survival of 6% for glioblastomas, 10% for grade 3 gliomas, and 40% to 60% for low-grade gliomas in the general population. 19 Most patients Abbreviations: FPN, first primary neoplasm; ALL, acute lymphoblastic leukemia; SPN, second primary neoplasm.
‫ء‬
These figures do not sum to the total number of gliomas (n ϭ 73) because one individual was excluded from the survival analysis (time between SPN diagnosis and death was zero).
†P H (two-sided) is from the likelihood ratio test for heterogeneity in the probability of dying across different levels of the specified explanatory factor, with adjustment for all other factors in the multivariable model. ‡P T is from the test for trend and is only for those factors with better than categoric measurement properties.
with glioma died from the glioma itself (79%), so it is possible that other factors that we were unable to determine contributed to survival. Surveillance, Epidemiology, and End Results (SEER) data indicate that 5-year relative survival is 64.4%, 55.2%, 32.8%, 13.6%, and less than 6% for patients diagnosed with cancer of the brain in 20-29, 30-39, 40-49, 50-59, and older than 60 years age groups, respectively.
16
In this study, most patients diagnosed with gliomas were younger than age 30 years, and prognosis would be expected to be better. However, treatment-induced gliomas are a special population and may represent a different biologic group of gliomas with associated genetic syndromes. For radiation-induced brain or spinal cord SPNs, it would generally be difficult or impossible to administer further radiotherapy because of the limited tolerance of the CNS to re-irradiation, even many years after radiotherapy for FPN.
In the general population, meningiomas constitute approximately 25% of primary brain tumors, 33 although there is evidence of under-reporting in young adults. 34 With the increasing use of computed tomography and MRI scanning, many meningiomas are detected as incidental findings. True incidence has been estimated to be one-third higher than cancer registry figures. 35 We identified 137 second primary meningiomas (55% total), including seven atypical and eight malignant (anaplastic) meningiomas (15 or 11% total), similar to that expected in adult first primary meningiomas (about 9.5%). 36 Mean interval overall from childhood cancer diagnosis to diagnosis of second primary meningioma was 23.1 years (23.5 years for benign and 15.9 for malignant meningiomas). There is evidence of malignant transformation of meningiomas with use of modern radiosurgery techniques, de novo, or with associated genetic syndromes [37] [38] [39] ; however, we were unable to determine in this study whether any malignant transformation occurred in the meningiomas included.
Age, sex, grade, histopathologic grade, treatment, tumor size, and hospital type affect survival after meningiomas. 33, 40, 41 In this study, survival was similar for males (84.0%; 95% CI, 72.6% to 91.1%) and females (81.7%; 95% CI, 69.9% to 89.3%) and was comparable to results from similar studies of primary adult meningiomas (approximately 80% 5-year survival [21] [22] [23] ). Grade was significant in the multivariate analysis (P ϭ .03), and meningioma-associated genetic syndromes had significantly poorer survival (P ϭ .03). This may indicate poorer underlying health in those with associated genetic syndromes. There were three deaths directly associated with NF1 and NF2 (of the 26 survivors with associated genetic syndromes), although only one of these was after a meningioma (Table 1) . Fiveyear relative survival in malignant meningiomas was reported to be 63% in the RARECARE study, 18 while results from studies of all meningiomas indicate that 5-year survival can be 80%. 19, [21] [22] [23] In this study, 5-year relative survival after malignant meningioma was 57.3% (95% CI, 17.2% to 84.0%) and for low-grade meningioma, it was 84.3% (95% CI, 76.5% to 90.0%). In the multivariate analysis, decade of treatment was significant (P ϭ .04), with the lowest hazard ratio in the group treated in the 1970s. This may reflect different treatment regimens used in different treatment eras or time of follow-up since diagnosis. Modern radiotherapy treatment regimens for brain tumors are thought to be much safer and include stereotactic and gamma knife radiosurgery. 37, 42 Our main limitation was that we did not collect detailed treatment information for these SPNs. However, the majority of SPNs were treated according to protocol: benign meningiomas (assumed to be radiation-induced by the treating clinician) were treated with surgery only. Secondary gliomas were treated with a combination of surgery with chemotherapy and/or radiotherapy, depending on aggressiveness of the tumor, underlying health of the patient, and previous dose of radiotherapy to the CNS. The majority of SPNs were treated before specialization of cancer surgery became widespread in the United Kingdom.
In conclusion, because of the increasing number of brain or spinal cord SPNs diagnosed after childhood cancer, these results are important in terms of counseling survivors regarding their prognosis and focusing clinical follow-up. Increasing awareness of the risk of SPNs should lead to use of interventions aimed at reducing risk, for example, reducing radiation dose and treated volume where possible for treatment of FPNs. For young children with low-grade gliomas, the use of radiotherapy may be delayed or possibly avoided by use of chemotherapy. There is increasing interest in the use of proton therapy to try to reduce the risk of SPNs. Proton therapy is a radiotherapy modality that exploits the well-defined path length of protons to achieve a well-defined dose distribution around the tumor.
In the United Kingdom, there are two clinical follow-up guidelines relating to survivors of childhood cancer 43, 44 ; however, neither suggests surveillance of childhood cancer survivors treated with cranial irradiation. The US-based Children's Oncology Group guidelines recommend alternate-year brain MRI scan for survivors with neurofibromatosis to begin 2 years after cranial irradiation, 45 and brain MRI scans for symptomatic survivors at a high risk of developing second primary brain tumors. We recommend that surveillance with regular MRI scan be considered for survivors of childhood cancer exposed to cranial irradiation to enable early diagnosis and treatment of brain and spinal cord SPNs.
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